Levo-Methasan (Levomethadone Hydrochloride)

Levomethadone hydrochloride acts as a full agonist at the µ‑opioid receptor, producing analgesic and euphoric effects. It also blocks NMDA receptors, which helps limit opioid tolerance and eases withdrawal symptoms, thereby supporting both pain control and opioid substitution therapy.

The appropriate dose of Levo-Methasan is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. No fixed regimen is provided here.

Safety data for levomethadone hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Levo-Methasan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levo-Methasan contains the levorotatory isomer of methadone, which may offer a more favorable side‑effect profile, particularly regarding cardiac QT prolongation. Both drugs act as µ‑opioid agonists, but levomethadone is often preferred when a lower dose achieves similar therapeutic effects.

Levo-Methasan should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure they are out of reach of children.

Levo-Methasan is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole; do not crush, split, or chew unless specifically instructed.

The most serious risks include respiratory depression, which can be life‑threatening, significant QT interval prolongation leading to cardiac arrhythmias, and severe hypotension. Patients should be monitored closely for signs of these events, especially during dose initiation or adjustment.

Levo-Methasan is contraindicated in individuals with known hypersensitivity to levomethadone or any component of the formulation, in patients with severe respiratory depression, uncontrolled asthma, or significant cardiac conduction disorders. Caution is also advised for those with severe hepatic impairment.